Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 694 | 40% |
| 2020 | 12 | 560 | 43% |
| 2021 | 16 | 600 | 46% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 97% of the cases CMS names in New Mexico; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 239 | 12,086−4.4%/yr | −4.4%/yr | 3.7 | 4% | 12,400 in 2030+0.5%/yr |
| Arizona | 85 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 8 | 559+9.8%/yr | +9.8%/yr | 2.00.7× | 0% | 1,040 in 2030+11%/yr |
| LAA occlusion & loop recorders |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
| 2024 |
| 618 |
| 54% |
| 2025 est. | ≈ 640 | – |
| 2026 est. | ≈ 640 | – |
| 2022 | 13 | 518 | 50% |
| 2023 | 12 | 533 | 53% |
| 2024 | 11 | 618 | 54% |
| 2025 from claims | – | 638 516–749 | 54% |
| 2026 forecast | – | 639 501–803 | 55% |
| 2027 forecast | – | 647 480–855 | 55% |
| 2028 forecast | – | 654 463–903 | 56% |
| 2029 forecast | – | 662 450–949 | 56% |
| 2030 forecast | – | 669 438–993 | 56% |
In 2025, 49% inpatient hospital, 51% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~640 | ~320 | ~320 |
| 2027 · ~650 | ~320 | ~320 |
| 2028 · ~650 | ~330 | ~330 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| 4,095−2.6%/yr |
| −2.6%/yr |
| 5.7 |
| 26% |
| 4,390 in 2030+1.2%/yr |
| Washington | 61 | 2,895−4.3%/yr | −4.3%/yr | 3.9 | 0% | 2,950 in 2030+0.3%/yr |
| Colorado | 38 | 1,903−1.6%/yr | −1.6%/yr | 4.1 | 0% | 2,210 in 2030+2.5%/yr |
| Oregon | 32 | 1,588−2.2%/yr | −2.2%/yr | 4.0 | 3% | 1,810 in 2030+2.2%/yr |
| Nevada | 21 | 1,111−3%/yr | −3%/yr | 4.0 | 2% | 1,240 in 2030+1.8%/yr |
| Utah | 22 | 921−2.8%/yr | −2.8%/yr | 4.4 | 0% | 900 in 2030−0.4%/yr |
| Montana | 15 | 883+1.5%/yr | +1.5%/yr | 4.7 | 0% | 880 in 20300%/yr |
| Idaho | 16 | 883+3.2%/yr | +3.2%/yr | 4.5 | 0% | 1,260 in 2030+6.1%/yr |
| Alaska | 6 | 384−0.5%/yr | −0.5%/yr | 3.2 | 26% | 440 in 2030+2.2%/yr |
| Wyoming | 3 | 122+2.7%/yr | +2.7%/yr | 1.1 | 0% | 190 in 2030+7.7%/yr |
| Hawaii | 3 | 114−16%/yr | −16%/yr | 0.9 | 0% | 130 in 2030+2.8%/yr |
| 5 |
| 431+11%/yr |
| +11%/yr |
| 1.60.6× |
| 2% |
| 1,040 in 2030+16%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 38% of company spending on these surgeons in 2025, +9 pts on 2024.
In 2025, 7 companies reported engagement with New Mexico’s surgeons worth $25K in consulting, speaking, meals and travel tied to these products, about $2,273 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.